HAEMONETICS CORP·4

May 7, 4:07 PM ET

Gordon Mikael 4

4 · HAEMONETICS CORP · Filed May 7, 2012

Insider Transaction Report

Form 4
Period: 2012-05-03
Gordon Mikael
President, Haemonetics Europe
Transactions
  • Exercise/Conversion

    Common Stock

    2012-05-03$55.14/sh+8,000$441,12012,442 total
  • Sale

    Common Stock

    2012-05-03$71.50/sh8,000$571,9874,442 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2012-05-03$71.50/sh8,000$571,9870 total
    Exercise: $55.14From: 2009-01-22Exp: 2015-01-22Common Stock (8,000 underlying)
Holdings
  • Non-Qualified Stock Option (right to buy)

    Exercise: $54.55From: 2009-10-22Exp: 2015-10-22Common Stock (3,812 underlying)
    3,812
  • Non-Qualified Stock Option (right to buy)

    Exercise: $54.99From: 2011-10-27Exp: 2017-10-27Common Stock (14,205 underlying)
    14,205
  • Non-Qualified Stock Option (right to buy)

    Exercise: $61.34From: 2012-10-25Exp: 2018-10-25Common Stock (17,565 underlying)
    17,565
  • Non-Qualified Stock Option (right to buy)

    Exercise: $52.94From: 2010-10-27Exp: 2016-10-27Common Stock (9,794 underlying)
    9,794
Footnotes (2)
  • [F1]Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.
  • [F2]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT